Rezdiffra vs Trulance
A side-by-side look at two gastrointestinal medications advertised on TV. Informational only — not medical advice.
| US Rezdiffra | US Trulance | |
|---|---|---|
| Generic name | resmetirom | plecanatide |
| Drug class | Thyroid Hormone Receptor-Beta Agonist | Guanylate Cyclase-C Agonist |
| Treats | Metabolic dysfunction-associated steatohepatitis (MASH) | Chronic constipation and IBS-C |
| Category | Gastrointestinal | Gastrointestinal |
| Manufacturer | Madrigal Pharmaceuticals | Salix (Bausch Health) |
| Year approved | 2024 | 2017 |
| FDA warning | Moderate warnings | Black box warning |
| Est. TV ad spend | — | — |
| Common side effects | Diarrhea, Nausea, Itching, Gallbladder problems | Diarrhea, Should not be used in young children (boxed warning), Abdominal pain, Bloating |
Rezdiffra
Frequently asked questions
Is Rezdiffra or Trulance better?
Neither is universally "better." Rezdiffra (resmetirom) and Trulance (plecanatide) are both used for gastrointestinal, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Rezdiffra and Trulance?
Rezdiffra is a Thyroid Hormone Receptor-Beta Agonist made by Madrigal Pharmaceuticals, while Trulance is a Guanylate Cyclase-C Agonist made by Salix (Bausch Health). See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Rezdiffra has the larger estimated TV advertising budget of the two.